WTO's COVID deal: more vaccine ‘enabler’ than IP waiver?

After several days and sleepless nights, members of the World Trade Organisation (WTO) finally agreed several key trade initiatives last week, including one that promises to suspend patent protection of the COVID-19 vaccines.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

13 July 2026 The company’s VP of IP explains how he is protecting the process, staying ahead of outside counsel, and why a biosimilar path is only a matter of time.

Americas

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

10 July 2026 Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.

Americas

Exelixis opens two-front patent dispute over Cabometyx copies

9 July 2026 Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.

More features

BioNTech and Pfizer secure big European win over mRNA patent

Pfizer’s US Paxlovid patent fight turns on a single error

GLP-1 patents and Africa: The COVID-19 lessons we still have not learned

Moderna: BioNTech is claiming work ‘it never did’

Heated LNP litigation puts Moderna and Acuitas in the spotlight

Moderna loses key mRNA patent in European vaccine fight

CureVac targets Moderna with 10-patent suit over Spikevax

Patent office fee increases: What applicants must know

WTO's COVID deal: more vaccine ‘enabler’ than IP waiver?

More on this story

Editor's picks

Editor's picks

More features